WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer

Oncotarget

Volumn 5, Issue 4, 2014, Pages 978-992

  Serafino, Annalucia ^a   Moroni, Noemi ^a   Zonfrillo, Manuela ^a   Andreola, Federica ^a   Mercuri, Luana ^a   Nicotera, Giuseppe ^a   Nunziata, Joseph ^b   Ricci, Riccardo ^b   Antinori, Armando ^b   Rasi, Guido ^c,d   Pierimarchi, Pasquale ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Colorectal carcinogenesis; Diagnostic therapeutic biomarkers; Inflammatory bowel disease; Multiparametric analysis; Wnt catenin pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; MYC PROTEIN; TUMOR MARKER; UVOMORULIN; WNT PROTEIN; APC PROTEIN; CADHERIN; PARAFFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CELL NUCLEUS; CELL TRANSPORT; CHEMOPROPHYLAXIS; COLON POLYPOSIS; COLORECTAL CANCER; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPORADIC COLORECTAL CANCER; TREATMENT RESPONSE; WNT SIGNALING PATHWAY; ANIMAL; CARCINOGENESIS; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE MODEL; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MALE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; CADHERINS; CARCINOGENESIS; COLORECTAL NEOPLASMS; CYCLIN D1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-MYC; RATS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84897408188     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1571     Document Type: Article

References (41)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63(1):11-30.
2. Finlay IG and McArdle CS. Occult hepatic metastases of colorectal carcinoma. Br J Surg. 1986; 73(9):732-735.
3. Bird NC, Mangnall D and Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006; 94(1):68-80.
4. Scheele J, Stangl R and Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg. 1990; 77(11):1241-1246.
5. Ballantyne GH and Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 1993; 71(12 suppl):4252-4266.
6. Wolmark N, Rockette H, Wickerham DL and Fisher B. Adjuvant therapy of Dukes' A, B and C adenocarcinoma of the colon with portal vein fluoracil hepatic infusion: Preliminary results of national surgical adjuvant breast and bowel project protocol C-02. J Clin Oncol. 1990; 8(9):1466-1475.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-1047.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22(1):23-30.
9. Grothey A and Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether double or single-agent therapy is used first line. J Clin Oncol. 2005; 23(36):9441-9442.
10. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13):905-914.
11. Madka V and Rao CV. Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer. Curr Cancer Drug Targets. 2013; 13(5):542-557.
12. Dreesen O and Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 2007; 3(1):7-17.
13. Whittaker S, Marais R and Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005.
14. Pandurangan AK. Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways. Asian Pac J Cancer Prev. 2013;14(4):2201-2205.
15. Eaden JA, Abrams KR and Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-535.
16. Nelson WJ and Nusse R. Convergence of Wnt, ß-Catenin, and Cadherin Pathways. Science. 2004; 303(5663):1483-1487.
17. Moon RT, Kohn AD. De Ferrari GV and Kaykas A. WNT and beta-catenin signaling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701.
18. Najdi R, Holcombe RF and Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 2011; 10:5. doi:10.4103/1477-3163.78111.
19. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W and He TC. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug. Targets. 2004; 4(8):653-671.
20. Anastas JN and Moon RT. WNT signaling pathways as therapeutic targets in cancer. Nat. Rev. Cancer. 2013; 13(1):11-26.
21. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein, B and Kinzler KW. Activation of ß-catenin-Tcf signaling in colon cancer by mutations in ß-catenin or APC. Science. 1997; 275(5307):1787-1790.
22. Claessen MM, Schipper ME, Oldenburg B, Siersema PD, Offerhaus GJ and Vleggaar FP. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol. 2010; 32(4):303-310.
23. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP and Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006; 27(12):2371-2382.
24. Munding J, Ziebarth W, Pox CP, Ladigan S, Reiser M, Hüppe D, Brand L, Schmiegel W, Tannapfel A and Reinacher-Schick AC. The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway. Carcinogenesis. 2012; 33(3):637-643.
25. Rogers AE and Nauss KM. Rodent models for carcinoma of the colon. Digest Dis Sci. 1985; 30(12 suppl):87S-102S.
26. Jackson PE, Cooper DP, O'Connor PJ and Povey AC. The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumors: tumor development in female SWR mice does not require a k-ras mutational event. Carcinogenesis. 1999; 20(3):509-513.
27. Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013; 8(9):1153-1164.
28. Patel R, Ingle A and Maru GB. Polymeric black tea polyphenols inhibit 1, 2-dimethylhydrazine induced colorectal carcinogenesis by inhibiting cell proliferation via Wnt/β-catenin pathway. Toxicol Appl Pharmacol. 2008; 227(1):136-146.
29. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993; 5(5):806-811.
30. Hajra KM and Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 2002; 34(3):255-268.
31. Neufeld KL, Zhang F, Cullen BR and White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep. 2000; 1(6)519-523.
32. Henderson BR and Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep. 2002; 3(9):834-839.
33. U.S. National Institutes of Health Service. ClinicalTrials.gov. http://clinicaltrials.gov (10 October 2013, date last accessed).
34. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F and Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005; 24(18):3054-3058.
35. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P and Rubinfeld B. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007; 67(11):5371-5379.
36. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P and Costa M. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One. 2010; 5(9):e12682.
37. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM and Cong F. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA. 2010; 107(35):15473-15478.
38. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, Zhang Y, Alpatov I, Zhang XA, Lang RA, Shi DL and Zheng JJ. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem. 2009; 284(24):16256-16263.
39. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW and Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102.
40. Eguchi M, Nguyen C, Lee SC and Kahn M. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem. 2005; 1(5):467-472.
41. Serafino A, Moroni N, Psaila R, Zonfrillo M, Andreola F, Wannenes F, Mercuri L, Rasi G and Pierimarchi P. Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/ß-catenin signaling. BBA-Mol Basis Dis. 2012; 1822(6):1004-1018